Light Horse’s CEO said the biotech’s initial focus will be on “high-value and historically challenging” oncology targets.

(Reuters) -Weight-loss drug developer Metsera, backed by ARCH Venture Partners, revealed a wider loss in its paperwork for a ...

Tenvie Therapeutics has unveiled with $200 million and the goal of transforming the neurological treatment landscape, nabbing ...

Light Horse Therapeutics is off to the races, rounding up a $62 million series A and tacking on a Novartis partnership that ...

About a year ago, Tenvie President and Chief Scientific Officer Tony Estrada approached Denali CEO Ryan Watts and others in ...

CI Financial Corp. ("CI" or the "Corporation") (TSX: CIX) today announced the commencement of the mailing of its management information circular and related shareholder meeting materials for the ...

CI Financial receives an interim court order concerning the transaction under which CI shares will be acquired by an ...

Backed by ARCH Venture Partners, F-Prime Capital and Mubadala Capital, the new company will develop a pipeline of ...

Advancing a deep pipeline of therapeutics focused on treating neurological, cardiometabolic, and ophthalmic diseasesLed by expert R&D ...

Tenvie Therapeutics is making hay from an R&D shift at Denali Therapeutics, acquiring several of its neuroscience drug ...